Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,865
archived clinical trials in
Multiple Sclerosis

Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
1057
mi
from
NY, NY
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
1057
mi
from
NY, NY
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
1301
mi
from
Schenectady, NY
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
1301
mi
from
Schenectady, NY
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
1282
mi
from
Staten Island, NY
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
1282
mi
from
Staten Island, NY
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
1193
mi
from
Syracuse, NY
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
1193
mi
from
Syracuse, NY
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
858
mi
from
Asheville, NC
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
858
mi
from
Asheville, NC
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
959
mi
from
Charlotte, NC
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
959
mi
from
Charlotte, NC
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
1068
mi
from
Raliegh, NC
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
1068
mi
from
Raliegh, NC
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
1043
mi
from
Sanford, NC
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
1043
mi
from
Sanford, NC
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
1135
mi
from
Wilmington, NC
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
1135
mi
from
Wilmington, NC
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
979
mi
from
Winston Salem, NC
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
979
mi
from
Winston Salem, NC
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
645
mi
from
Bismarck, ND
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
645
mi
from
Bismarck, ND
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
900
mi
from
Canton, OH
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
900
mi
from
Canton, OH
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
746
mi
from
Dayton, OH
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
746
mi
from
Dayton, OH
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
959
mi
from
Monaca, PA
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
959
mi
from
Monaca, PA
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
1225
mi
from
Philadelphia, PA
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
1421
mi
from
Cranston, RI
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
1421
mi
from
Cranston, RI
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
618
mi
from
Nashville, TN
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
618
mi
from
Nashville, TN
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
664
mi
from
Tullahoma, TN
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
664
mi
from
Tullahoma, TN
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
349
mi
from
Dallas, TX
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
349
mi
from
Dallas, TX
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
360
mi
from
Mansfield, TX
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
360
mi
from
Mansfield, TX
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
583
mi
from
San Antonio, TX
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
583
mi
from
San Antonio, TX
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
1114
mi
from
Henrico, VA
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
1114
mi
from
Henrico, VA
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
1111
mi
from
Richmond, VA
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
1111
mi
from
Richmond, VA
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
979
mi
from
Roanoke, VA
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
979
mi
from
Roanoke, VA
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
1115
mi
from
Vienna, VA
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
1115
mi
from
Vienna, VA
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
1201
mi
from
Spokane, WA
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
1201
mi
from
Spokane, WA
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
970
mi
from
Morgantown, WV
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
970
mi
from
Morgantown, WV
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
630
mi
from
Milwaukee, WI
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
630
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
630
mi
from
Milwaukee, WI
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
630
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
659
mi
from
Neenah, WI
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
659
mi
from
Neenah, WI
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
1299
mi
from
Coconut Creek, FL
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
1299
mi
from
Coconut Creek, FL
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
1298
mi
from
Sunrise, FL
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
1298
mi
from
Sunrise, FL
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
5180
mi
from
Linz,
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
5180
mi
from
Linz,
Click here to add this to my saved trials
Project Get Fit With MS: Guidelines for Exercise Training and Fitness Outcomes in MS
Project GET FIT With MS: Guidelines for Exercise Training and Fitness Outcomes in MS
Status: Enrolling
Updated:  12/1/2015
University of Illinois at Urbana-Champaign
mi
from
Urbana-Champaign, IL
Project Get Fit With MS: Guidelines for Exercise Training and Fitness Outcomes in MS
Project GET FIT With MS: Guidelines for Exercise Training and Fitness Outcomes in MS
Status: Enrolling
Updated: 12/1/2015
University of Illinois at Urbana-Champaign
mi
from
Urbana-Champaign, IL
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
523
mi
from
Albuquerque, NM
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
523
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
779
mi
from
Salt Lake City, UT
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
779
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
1330
mi
from
Berkeley, CA
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
1330
mi
from
Berkeley, CA
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
1210
mi
from
Fresno, CA
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
1210
mi
from
Fresno, CA
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
1158
mi
from
Newport Beach, CA
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
1158
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
402
mi
from
Aurora, CO
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
402
mi
from
Aurora, CO
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
1117
mi
from
Tampa, FL
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
1117
mi
from
Tampa, FL
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
1227
mi
from
Vero Beach, FL
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
1227
mi
from
Vero Beach, FL
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
378
mi
from
Northbrook, IL
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
378
mi
from
Northbrook, IL
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
829
mi
from
Farmington Hills, MI
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
829
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
552
mi
from
Minneapolis, MN
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
1064
mi
from
Raleigh, NC
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
1064
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
726
mi
from
Cincinnati, OH
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
726
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
903
mi
from
Uniontown, OH
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
903
mi
from
Uniontown, OH
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
479
mi
from
Cordova, TN
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
479
mi
from
Cordova, TN
Click here to add this to my saved trials
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/10/2015
Clinical Research Facility
779
mi
from
Knoxville, TN
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/10/2015
Clinical Research Facility
779
mi
from
Knoxville, TN
Click here to add this to my saved trials